NASDAQ: ITRMIterum Therapeutics PLC Stock
$0.35+0.03 (+9.38%)
Updated Jan 22, 2026
ITRM Price
$0.35
Fair Value Price
N/A
Market Cap
$18.48M
52 Week Low
$0.26
52 Week High
$1.75
P/E
-0.49x
P/B
-2.5x
P/S
78.73x
PEG
N/A
Dividend Yield
N/A
Revenue
$390.00k
Earnings
-$26.96M
Gross Margin
-146.4%
Operating Margin
-6,287.18%
Profit Margin
-6,913.1%
Debt to Equity
-5.4
Operating Cash Flow
-$20M
Beta
1.14
Next Earnings
Mar 12, 2026
Ex-Dividend
N/A
Next Dividend
N/A
ITRM Overview
Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing and commercializing anti-infectives in Ireland, Bermuda, and the United States. It is developing sulopenem, a novel anti-infective compound with oral and IV formulations that is in Phase III clinical trials for the treatment of uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections. The company was incorporated in 2015 and is headquartered in Dublin, Ireland.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine ITRM's potential to beat the market
- ITRM doesn't meet the minimum data requirements for our proprietary Zen Ratings model. Learn more about Zen Ratings.
Zen Rating Component Grades
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
ITRM
RankedUnranked of 488
RankedUnranked of 488
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $5.42 | A | |
| $19.93 | A | |
| $6.75 | A |
Be the first to know about important ITRM news, forecast changes, insider trades & much more!
ITRM News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how ITRM scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
ITRM is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
ITRM is unprofitable, so we are unable to assess its PEG ratio
PEG Value Valuation
ITRM's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
There are 30 more ITRM due diligence checks available for Premium users.
Valuation
ITRM price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.49x
Industry
161.72x
Market
47.89x
ITRM price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
-2.5x
Industry
5.67x
ITRM's financial health
Profit margin
Revenue
$390.0k
Net Income
-$9.0M
Profit Margin
-2,302.3%
ITRM's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
ITRM's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$32.5M
Liabilities
$39.9M
Debt to equity
-5.4
ITRM's short-term assets ($13.73M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
ITRM's long-term liabilities ($33.45M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
ITRM's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
ITRM's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$7.4M
Investing
-$12.0k
Financing
$5.4M
ITRM's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
ITRM vs Biotech Stocks
Iterum Therapeutics Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.